During the corresponding time, Strata Skin Sciences Inc saw a revenue deteriorated by -2.97 % year on year, sequentially revenue grew by 50.26 %. While revenue at the Strata Skin Sciences Inc's corporate clients
Strata Skin Sciences Inc's Comment on Sales, Marketing and Customers
The company markets XTRAC excimer laser systems primarily for treating autoimmune dermatological skin disorders, including psoriasis, vitiligo, atopic dermatitis, eczema, and leukoderma. The XTRAC system is FDA-cleared for these treatments. The VTRAC UV light lamp system is marketed exclusively in international markets. In the U.S., the XTRAC excimer laser is sold mainly to dermatologists under a recurring revenue model, with over 1,000 systems in use and 842 included in the recurring procedures revenue model as of December 31, 2025. The target U.S. market consists of approximately 3,500 dermatologists. The company acquired the Pharos business in 2021, which provides an opportunity to convert its customer base to the XTRAC system.
: This article presents a critical analysis of recent advancements in dermatological treatments focusing on two pivotal studies: the application of 308-nm Excimer laser in treating the uncommon subtype of Mycosis Fungoides, poikilodermatous mycosis fungoides (pMF), and the efficacy and safety of STRATA Skin Sciences TheraClearX Acne Therapy System. The emerging clinical evidence for these therapies may offer substantial benefits for patients with these challenging dermatological conditions. In dermatology, innovative laser and photopneumatic technologies are paving the way for novel treatment avenues. Recent reports highlight significant progress in the treatment of both a rare variant of cutaneous lymphom...
Vitiligo, an autoimmune skin disorder characterized by the loss of pigment, poses significant therapeutic challenges. Recent advancements have highlighted the potential for combination therapies to enhance treatment efficacy and safety for patients. A pivotal study, published in the International Journal of Dermatology , provides new evidence supporting the combined use of STRATA Skin Sciences’ Excimer Laser and Janus kinase (JAK) inhibitors, presenting a promising option in the clinical management of vitiligo.In an investigator-initiated randomized controlled trial, the combination therapy demonstrated significant superiority over monotherapy options. The study involved a cohort of patients diagnosed wit...
In a notable development that may signal a turning tide for STRATA Skin Sciences, Inc. (NASDAQ: SSKN), the medical technology firm has recently secured a favorable ruling from the United States District Court for the Eastern District of Pennsylvania. This court order comes as a positive advance in the company’s ongoing complaint against a trio of defendants: LaserOptek America Corp. Monarch Aesthetic Services, Inc. (operating as Monarch Laser Services), and The Pinnacle Health Group.STRATA, which specializes in the development and commercialization of innovative solutions for dermatological conditions, has been navigating a challenging year. With year-to-date shares reflecting a decline of 40.55%, the comp...
Acne is a common dermatological condition that affects millions of people worldwide. It can lead to physical discomfort, emotional distress, and a negative impact on self-esteem. Many individuals try a variety of remedies and treatments to combat their acne, often without achieving desired results. However, the study conducted on TheraClearX shows promising outcomes for those struggling with this condition.The research aimed to determine the safety, efficacy, tolerability, and patient satisfaction of TheraClearX on a diverse range of individuals with varying skin types. The study demonstrated that TheraClearX was successful in improving acne lesions across all Fitzpatrick skin types. The Fitzpatrick scale ca...
In a significant achievement for medical technology company Strata Skin Sciences, their installed base of TheraClearX devices reached a milestone of over 100 at the end of March 2024. The company, dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, has experienced remarkable growth in its product adoption. However, amidst this achievement, Strata Skin Sciences has also faced challenges with declining revenues. This article will explore the success of TheraClearX devices and delve into the causes behind the recent decline in the company s revenue.Part 1: The Success of TheraClearX DevicesStrata Skin Sciences TheraClearX devices have emerge...
Skin Care Company Strata Skin Sciences Achieves Long-standing Exclusive Distribution Agreements in China and Japan, Boosting Revenue But Facing ChallengesIn recent news, Strata Skin Sciences, a leading skincare company, has announced the renewal of its exclusive distribution agreements in China and Japan. These agreements have been maintained for over a decade by distributors in both countries, and they collectively contributed to a significant 46% of the company s total international revenue in 2023. This development comes at a crucial time for the company as it strives to combat a decline in revenue.The long-standing partnership between Strata Skin Sciences and its distributors in China and Japan has prov...
Strata Skin Sciences Inc’s Comment on Sales, Marketing and Customers
The company markets XTRAC excimer laser systems primarily for treating autoimmune dermatological skin disorders, including psoriasis, vitiligo, atopic dermatitis, eczema, and leukoderma. The XTRAC system is FDA-cleared for these treatments. The VTRAC UV light lamp system is marketed exclusively in international markets. In the U.S., the XTRAC excimer laser is sold mainly to dermatologists under a recurring revenue model, with over 1,000 systems in use and 842 included in the recurring procedures revenue model as of December 31, 2025. The target U.S. market consists of approximately 3,500 dermatologists. The company acquired the Pharos business in 2021, which provides an opportunity to convert its customer base to the XTRAC system.
Sources:
Strata Skin Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Strata Skin Sciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Strata Skin Sciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
71.11 %